Skip to content

NHLBI EIA R35 Guide

Updated 5 official sources

Quick Answer: RFA-HL-26-003 NHLBI EIA eligibility turns on 7 checks: active NHLBI R01-equivalent portfolio, qualifying ESI R01, single-PD/PI condition, effort commitment, HLBS research-program fit, $700,000 annual direct-cost cap, and seven-year plan.

Full answer and how we checked it

The last due date is February 19, 2027, and an award means giving up most of your other NHLBI single-PI grants.

Who this is for: NHLBI-funded emerging investigators, department chairs, research administrators, grant strategists, and sponsored-research offices deciding whether the NHLBI EIA R35 is the right route.

Data note: This guide uses the official NIH RFA-HL-26-003 NOFO, Grants.gov listing 353822, NIH clinical-trial policy pages, NIH RePORTER (opens in a new tab) award records, and Grantsights award-data signals checked on May 19, 2026 and rechecked October 9, 2026.

In this guide

Quick Facts

Agency
HHS
Deadline
Apr 28, 2027
Status
Open

Assistance Listing 93.233: all awards

Source: USASpending.gov FY2024

These figures cover all National Institutes of Health awards under Assistance Listing 93.233, of every award type. They are not figures for the award this guide describes, and one award of that kind can be far smaller.

Total Awards (FY2024, whole listing)
131
Avg Award (whole listing)
$3,121,419
Median Award (whole listing)
$2,702,841

Data last verified: May 21, 2026

According to NIH RFA-HL-26-003 (opens in a new tab), the NHLBI Emerging Investigator Award supports experienced PDs/PIs who are currently PDs/PIs on at least two NHLBI R01-equivalent awards, with one being an NHLBI-funded NIH Early Stage Investigator R01 award. NIH marks the R35 as Clinical Trial Optional.

This route is not for every strong early-career researcher. The eligibility screen is exacting, and the award is meant to support an NHLBI-relevant research program rather than a single project.

Use this guide with the live Grantsights program record. Then compare NIH grants complete guide, what is a NOFO, NHLBI clinical trial pilot guide, NHLBI Catalyze R33 guide, and the Grantsights grant database.

7 RFA-HL-26-003 Eligibility Stop Checks

Stop checkStrong NHLBI EIA signalRed flag
R01-equivalent portfolioAt least two NHLBI R01-equivalent awardsPortfolio does not qualify
ESI R01One qualifying NHLBI-funded ESI R01 existsNo qualifying ESI R01
Award statusRequired award status rules are metNo-cost extension risk
EffortSix person months can be committedEffort cannot be protected
Program fitHLBS research program is coherentSingle-project story
BudgetUp to $700K direct costs per year fitsBudget exceeds or lacks rationale
TermSeven-year program plan is crediblePlan is too narrow

Strong investigators sometimes assume "emerging" means broad early-career eligibility. For this NOFO, the existing NHLBI award portfolio is the gate.

5 Source Facts Applicants Should Know

According to NIH, the NHLBI EIA is intended to support a research program, rather than a research project, and may provide support for up to 7 years.

According to NIH, the PD/PI must be on at least two NHLBI R01-equivalent awards, defined as R01, DP1, or DP2. One must be an NHLBI-funded ESI R01. NIH also says the PD/PI must commit at least six person months throughout the award.

FactSource-backed read
Funding numberRFA-HL-26-003
Activity codeR35 Outstanding Investigator Award
Clinical trial statusClinical Trial Optional
BudgetUp to $700,000 direct costs per year
Project periodUp to 7 years
Due datesFebruary 19, 2026 (passed); February 19, 2027 (last)
Review for February 2027July 2027 review, October 2027 council, December 2027 earliest start
ExpirationApril 29, 2027
Funding planUp to 20 new R35 awards and up to $20 million in total costs a year in FY2026 to FY2028, shared with a companion NOFO
Live listingGrants.gov listing 353822

Two date details matter. The NOFO still says a letter of intent is due 30 days before the deadline, but NIH stopped requesting or accepting letters of intent under NOT-OD-26-019 (opens in a new tab), so there's nothing to send. And the February 2027 round has no resubmission date, because only new applications are allowed.

The Fine Print on Eligibility

NHLBI checks eligibility itself after the due date, and the NOFO (opens in a new tab) is more specific than "two R01s." At least one of the two qualifying R01-equivalent awards must be single-PD/PI, must not be in a no-cost extension, and must not be an NIH-defined clinical trial unless it's a mechanistic trial. The other qualifying award can be multi-PD/PI, in a first no-cost extension, or a clinical trial. One of the two must be an NHLBI-funded Early Stage Investigator R01. Multi-PD/PI applications aren't accepted, and an application missing its letters of support won't go to review.

The six person months is defined precisely: 50% effort on a 12-month appointment, 66.67% on a 9-month appointment, or 100% on a 6-month appointment, held for the whole award. Effort on teaching, administration, and clinical duties doesn't count toward it.

"Clinical Trial Optional" also has a limit. Mechanistic trials are allowed, but Phase I, II, III, or T4 non-mechanistic clinical trials make an application nonresponsive.

What You Give Up if You Win

NHLBI expects the EIA to replace your current NHLBI single-project, single-PD/PI research grants, and the AOR must acknowledge that in the application. Training grants, resource grants such as P30, R24, and U24, contracts, cooperative agreements, SBIR/STTR, conference grants, program project and center grants, and Catalyze grants are exempt. NHLBI won't fund new individual research grants for you during the EIA except near its end or during a no-cost extension.

You can submit an R01 and an EIA in parallel. If both are selected, you take one or the other. The award amount is set by NHLBI and is expected to be commensurate with your current NHLBI support, so the $700,000 cap isn't a target.

What NIH Doesn't Tell You

Within 21 days, answer 4 practical questions. First, this is a portfolio eligibility problem before it is a writing problem. If the R01-equivalent and ESI R01 rules fail, a good program vision cannot fix the application.

Second, the award must read as a program. An investigator whose related NHLBI-funded projects form a clear HLBS program may fit. An investigator with two unrelated projects may need a stronger program architecture first.

Third, the effort commitment is strategic. Six person months is a real commitment, and the institution should understand the tradeoff.

Fourth, reviewers score the investigator as much as the plan. The NOFO-specific questions ask how the PD/PI has shown outstanding productivity, how past work has advanced HLBS research, whether the program is broad and ambitious enough, whether the PD/PI shows promise as a mentor and in professional service, and whether the institutional letter of support commits to the PD/PI for the whole award.

6 Evidence Assets That Make This Application Stronger

Within 21 days, build 6 evidence assets. Asset 1 is the eligibility memo. List current NHLBI R01-equivalent awards, ESI R01 status, PD/PI role, award status, and no-cost extension details.

Asset 2 is the program-vision memo. Explain the unifying HLBS research program across projects.

Asset 3 is the consolidation map. Show how current and future research directions fit the R35 program rather than competing projects.

Asset 4 is the effort plan. Show six person months, leadership roles, lab structure, mentoring, and institutional support.

Asset 5 is the budget plan. Tie up to $700,000 direct costs per year to program needs.

Asset 6 is the route memo. Compare EIA R35 with new R01s, R01 renewals, OIA, R56, R21, clinical-trial NOFOs, and foundation routes.

5 Route Choices Before Drafting

Within 21 days, compare 5 routes.

RouteBetter first read when...Why
NHLBI EIA R35Eligibility and program vision both fitR35 route fits
R01 renewalOne project needs continuationProject route may fit
New R01New project is separateStandard route may fit
OIA or other R35Investigator stage differsDifferent R35 may fit
R21 or foundationIdea is early or exploratorySmaller route may fit

Warning: if the applicant cannot prove ESI R01 and NHLBI R01-equivalent eligibility in one page, don't start with the EIA narrative.

6 Bad-Fit Signals

First, the PD/PI lacks two qualifying NHLBI R01-equivalent awards. Second, no qualifying ESI R01 exists. Third, the program is a collection of unrelated projects.

Fourth, effort cannot be protected. Fifth, budget is not tied to the research program. Sixth, clinical-trial status is unclear.

These signals are gate risks.

21-Day NHLBI EIA Readiness Plan

Days 1 through 3 should verify R01-equivalent awards, ESI R01 status, award status, effort, and clinical-trial boundary. Days 4 through 7 should write the eligibility and program-vision memos.

Days 8 through 12 should build consolidation, effort, and budget plans. Days 13 through 16 should compare EIA with R01, renewal, R21, and other R35 routes. Days 17 through 21 should complete NIH application checks and institutional commitment review.

Who Has Received the NHLBI EIA

5 new awards under RFA-HL-26-003 appear in FY2026 NIH RePORTER (opens in a new tab) records pulled by Grantsights on October 9, 2026. They came from the February 19, 2025 round, whose earliest start date was December 2025; awards from the February 2026 round can start no earlier than December 2026.

AwardOrganizationProgram topicFY2026 direct costs
R35HL184269Icahn School of Medicine at Mount SinaiHemogenic mesoderm heterogeneity and function$699,955
R35HL184260Henry Ford Health + Michigan State University Health SciencesCircadian medicine for shift workers$700,000
R35HL184172University of VirginiaImaging sodium in lymphatic disease$597,526
R35HL183578Stanford UniversityEndothelial and cardiomyocyte crosstalk in cardiomyopathy$500,000
R35HL183474Dana-Farber Cancer InstituteClonal dynamics in hematopoiesis$250,000

Grantsights analysis of those records and the earlier RFA-HL-23-005 awards shows first-year direct costs from about $170,000 to $721,000. That spread fits the NOFO's rule that the award tracks each investigator's existing NHLBI support. Topics run across heart, lung, blood, vascular, and sleep or circadian science, and most recipients are at academic medical centers or research institutes.

6 Final Research Checks Before Submission

Within 21 days, finish 6 final checks. Check 1 is the NIH RFA-HL-26-003 NOFO (opens in a new tab). Check 2 is NIH application-guide compliance. Check 3 is NHLBI R01-equivalent portfolio. Check 4 is ESI R01 status. Check 5 is effort commitment. Check 6 is clinical-trial boundary.

You're ready when the team can state the two qualifying awards, ESI R01, program vision, effort commitment, budget, and route reason in 6 direct sentences.

4 Decision Questions Before Drafting

Within 21 days, ask 4 decision questions. Question 1: "Do you have at least two qualifying NHLBI R01-equivalent awards?" Question 2: "Is one a qualifying NHLBI ESI R01?" Question 3: "Can you commit six person months?" Question 4: "Does the work read as one research program?"

If question 1 or 2 fails, stop and plan around an R01 renewal or new R01 instead.

3 Last-Mile Checks For NHLBI Investigators

Within 21 days, run 3 last-mile checks. Check 1 is award-portfolio proof. Check 2 is program-vision proof. Check 3 is effort proof.

If those checks are weak, talk to NHLBI before building the narrative. A final note for applicants: write the EIA fit sentence before the overview. In 2 sentences, state the qualifying awards, ESI R01, HLBS program, effort, budget, and reason R35 is the best route.

Sources

Largest awards active in FY2024

One row per recipient, its largest award | 131 Assistance Listing records | Avg: $3.1M

REAL DATA
1

Beth Israel Deaconess Medical Center, Inc.

MA

$16.3M
2

Brigham & Womens Hospital Inc

MA

$14.0M

Use the visible recipient rows as free source context

This program has no reviewed paid report today.

No reviewed paid report is currently offered for this program. The visible source rows remain free.

Frequently Asked Questions

What does RFA-HL-26-003 support?

It supports NHLBI-funded emerging investigators with long-term flexible R35 support for an HLBS research program.

What eligibility rule is central?

NIH says the PD/PI must be on at least two NHLBI R01-equivalent awards, and one must be an NHLBI-funded ESI R01.

What is the budget cap?

Applications may request up to $700,000 in direct costs per year.

How long can support run?

Applications may request up to seven years.

When is the next due date?

February 19, 2027 is the only remaining due date. The February 19, 2026 date has passed, and the NOFO expires April 29, 2027.

Who should skip this route?

Skip it if the PD/PI does not meet the current NHLBI R01-equivalent and ESI R01 eligibility rules or cannot commit the required effort.

Last updated October 9, 2026. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.